Lobbying Information
Subject Matter Details
Legislative Proposal, Bill or Resolution, Regulation
- Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
Policies or Program
- Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
- To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
- To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
- To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Correctional Service of Canada (CSC)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Indigenous Services Canada (ISC)
-
National Defence (DND)
-
Senate of Canada
In-house Corporation Details
Description of activities
At Organon, our mission is to deliver impactful medicines and solutions for a healthier every day. We build upon our strong foundation of more than 60 established medicines and solutions across a range of areas including reproductive health, heart disease, breast cancer, allergies and asthma.
In Canada, Organon is a leader in areas such as contraception, fertility, hormone therapy, biosimilars, cardiovascular and markets more than 30 pharmaceutical and biological products. Based in Montréal, Québec, Organon employs approximately 115 people across Canada
Responsible officer name and position during the period of this registration
Michael Casia,
President & Managing Director
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
300-16766 Route Transcanadienne
Kirkland, QC H9H 4M7
Canada
Telephone number:
800-387-1326
Parent Company Information
- Organon & Co., Inc
-
30 Hudson Street, 33rd floor
Jersey City, NJ 07302
United States of America
Subsidiary Beneficiary Information
Organon Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Michael Casia,
President & Managing Director |
No public offices held
- Valérie Joseph,
Regulatory Affairs & Pharmacovigilance |
No public offices held
- Jeffery Malawski,
Policy & External Affairs |
No public offices held
- Anne Mayrand,
Head, Legal Affairs and Compliance |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Geneviève Gauthier,
Associate Director, Policy & Access |
No public offices held
- Hugues Poulin,
Associate Director, Policy & Access |
No public offices held
